45 results on '"Mitzner S"'
Search Results
2. A liver cell-based biosensor in patients with septic shock: results of a second prospective study: OP-123
- Author
-
Sauer, M, Haubner, C, Brenner, J, Mencke, T, Nöldge-Schomburg, G, Potschka, H, and Mitzner, S
- Published
- 2013
3. A new device for screening hepatotoxicity: test results with the muscle relaxant rocuronium: OP-110
- Author
-
Sauer, M, Piel, I, Haubner, C, Mencke, T, Nöldge-Schomburg, G, Potschka, H, and Mitzner, S
- Published
- 2011
4. Extracorporeal cell therapy of patients with septic shock using human donor granulocytes: OP-087
- Author
-
Mitzner, S, Sauer, M, and Altrichter, J
- Published
- 2011
5. 2230Results from the CAMI1 Study: selective CRP apheresis as a new treatment option in acute myocardial infarction
- Author
-
Garlichs, C, primary, Torzewski, J, additional, Sheriff, A, additional, Pfluecke, C, additional, Darius, H, additional, Lehrke, S, additional, Horstkotte, J, additional, Heigl, F, additional, Ince, H, additional, Mitzner, S, additional, Nordbeck, P, additional, Butter, C, additional, Zaenker, M, additional, and Ries, W, additional
- Published
- 2019
- Full Text
- View/download PDF
6. Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450
- Author
-
Löhr, M, Müller, P, Karle, P, Stange, J, Mitzner, S, Jesnowski, R, Nizze, H, Nebe, B, Liebe, S, Salmons, B, and Günzburg, WH
- Published
- 1998
- Full Text
- View/download PDF
7. Systemic long-term delivery of antibodies in immunocompetent animals using cellulose sulphate capsules containing antibody-producing cells
- Author
-
Pelegrin, M, Marin, M, Noël, D, Rio, M Del, Saller, R, Stange, J, Mitzner, S, Günzburg, WH, and Piechaczyk, M
- Published
- 1998
- Full Text
- View/download PDF
8. Results of a liver cells-based biosensor in patients with septic shock: OP109
- Author
-
Sauer, M, Haubner, C, Mencke, T, Nöldge-Schomburg, G, Altrichter, J, Stange, J, and Mitzner, S R
- Published
- 2009
9. Extracorporeal treatment of sepsis with granulocyte-based bioreactors: KL026
- Author
-
Mitzner, S, Altrichter, J, and Sauer, M
- Published
- 2009
10. Extracorporeal immune cell support allows for acute regeneration in bacterial sepsis: OP68
- Author
-
Mitzner, S, Altrichter, J, Sauer, M, Nöldge-Schomburg, G, and Schmidt, R
- Published
- 2007
11. Pharmacokinetics of ciprofloxacin and levofloxacin in patients with liver cirrhosis: influence of albumin dialysis by Molecular Adsorbent Recirculating System (MARS). Is a dosage adjustment necessary?
- Author
-
Majcher-Peszynska, J., Klammt, S., Berg, A., Stange, J., Mundkowski, R., Mitzner, S. R., and Drewelow, B.
- Subjects
ddc: 610 ,610 Medical sciences ,Medicine - Abstract
Bacterial infections are one of the most important clinical problems and contribute to the high mortality rate in patients with decompensated liver cirrhosis. Fluoroquinolones are highly effective drugs and are frequently used in patients with cirrhosis of the liver, especially for prophylaxis of spontaneous[for full text, please go to the a.m. URL], Infektiologie Update 2016; 25. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG)
- Published
- 2016
12. SP247CYTOKINE ADSORPTION IS A PROMISING TOOL FOR THERAPY OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH)
- Author
-
Frimmel, S., primary, Bogdanow, S., additional, Schipper, J., additional, Hinz, M., additional, Mitzner, S., additional, and Koball, S., additional
- Published
- 2017
- Full Text
- View/download PDF
13. Alterationen der kornealen Nervenfasermorphologie bei Patienten mit einer terminalen Niereninsuffizienz
- Author
-
Kozlova, Kristine, Zhivov, A., Peschel, S., Kundt, G., Tieß, M., Mitzner, S., Stachs, O., Guthoff, R., and Jünemann, A.
- Subjects
ddc: 610 ,610 Medical sciences ,Medicine - Abstract
Einführung: Die Polyneuropathie bei Dialysepatienten ist multifaktoriell – insbesondere wird sie durch Urämietoxine, Bluthochdruck, Ischämien und Diabetes begünstigt. Ziel dieser Arbeit ist es, Änderungen der Hornhautnerven bei Dialyse-Patienten in Abhängigkeit vom[for full text, please go to the a.m. URL], 65. Tagung der Vereinigung Norddeutscher Augenärzte
- Published
- 2015
- Full Text
- View/download PDF
14. The costs of acute-on-chronic liver failure: A bottom-up analysis based on individualpatient data. 6th European Conference on Health Economics. Health Economics without Frontiers, 6.-9. Juli 2006 in Budapest
- Author
-
Wasem, Jürgen, Hessel, Franz, and Mitzner, S.
- Subjects
Wirtschaftswissenschaften - Abstract
Poster-Abstract
- Published
- 2006
15. AKI - Clinical
- Author
-
Gok Oguz, E., primary, Olmaz, R., additional, Turgutalp, K., additional, Muslu, N., additional, Sungur, M. A., additional, Kiykim, A., additional, Van Biesen, W., additional, Vanmassenhove, J., additional, Glorieux, G., additional, Vanholder, R., additional, Chew, S., additional, Forster, K., additional, Kaufeld, T., additional, Kielstein, J., additional, Schilling, T., additional, Haverich, A., additional, Haller, H., additional, Schmidt, B., additional, Hu, P., additional, Liang, X., additional, Chen, Y., additional, LI, R., additional, Jiang, F., additional, LI, Z., additional, Shi, W., additional, Lim, C. C. W., additional, Chia, C. M. L., additional, Tan, A. K., additional, Tan, C. S., additional, Ng, R., additional, Subramani, S., additional, Perez de Jose, A., additional, Bernis Carro, C., additional, Madero Jarabo, R., additional, Bustamante, J., additional, Sanchez Tomero, J. A., additional, Chung, W., additional, Ro, H., additional, Chang, J. H., additional, Lee, H. H., additional, Jung, J. Y., additional, Fazzari, L., additional, Giuliani, A., additional, Scrivano, J., additional, Pettorini, L., additional, Benedetto, U., additional, Luciani, R., additional, Roscitano, A., additional, Napoletano, A., additional, Coclite, D., additional, Cordova, E., additional, Punzo, G., additional, Sinatra, R., additional, Mene, P., additional, Pirozzi, N., additional, Shavit, L., additional, Manilov, R., additional, Algur, N., additional, Wiener-Well, Y., additional, Slotki, I., additional, Pipili, C., additional, Vrettou, C. S., additional, Avrami, K., additional, Economidou, F., additional, Glynos, K., additional, Ioannidou, S., additional, Markaki, V., additional, Douka, E., additional, Nanas, S., additional, De Pascalis, A., additional, Cofano, P., additional, Proia, S., additional, Valletta, A., additional, Vitale, O., additional, Russo, F., additional, Buongiorno, E., additional, Filiopoulos, V., additional, Biblaki, D., additional, Lazarou, D., additional, Chrysis, D., additional, Fatourou, M., additional, Lafoyianni, S., additional, Vlassopoulos, D., additional, Zakiyanov, O., additional, Kriha, V., additional, Vachek, J., additional, Svarcova, J., additional, Zima, T., additional, Tesar, V., additional, Kalousova, M., additional, Kaushik, M., additional, Ronco, C., additional, Cruz, D., additional, Zhang, L., additional, Zhang, W., additional, Chen, N., additional, Ejaz, A. A., additional, Kambhampati, G., additional, Ejaz, N., additional, Dass, B., additional, Lapsia, V., additional, Arif, A. A., additional, Asmar, A., additional, Shimada, M., additional, Alsabbagh, M., additional, Aiyer, R., additional, Johnson, R., additional, Chen, T.-H., additional, Chang, C.-H., additional, Chang, M.-Y., additional, Tian, Y.-C., additional, Hung, C.-C., additional, Fang, J.-T., additional, Yang, C.-W., additional, Chen, Y.-C., additional, Cantaluppi, V., additional, Quercia, A. D., additional, Figliolini, F., additional, Giacalone, S., additional, Pacitti, A., additional, Gai, M., additional, Guarena, C., additional, Leonardi, G., additional, Biancone, L., additional, Camussi, G., additional, Segoloni, G. P., additional, De Cal, M., additional, Lentini, P., additional, Clementi, A., additional, Virzi, G. M., additional, Scalzotto, E., additional, Lacquaniti, A., additional, Donato, V., additional, Fazio, M. R., additional, Lucisano, S., additional, Cernaro, V., additional, Lupica, R., additional, Buemi, M., additional, Helvaci, I., additional, Anik, E., additional, Wani, M., additional, Wani, D. I., additional, Bhat, D. M. A., additional, Banday, D. K., additional, Najar, D. M. S., additional, Reshi, D. A. R., additional, Palla, D. N. A., additional, Iglesias, P., additional, Olea, T., additional, Vega-Cabrera, C., additional, Heras, M., additional, Bajo, M. A., additional, Del Peso, G., additional, Arias, M. J., additional, Selgas, R., additional, Diez, J. J., additional, Daher, E., additional, Costa, P. L., additional, Pereira, E. N. S., additional, Santos, R. D. P., additional, Abreu, K. L., additional, Silva Junior, G., additional, Pereira, E. D. B., additional, Raimundo, M., additional, Crichton, S., additional, Syed, Y., additional, Martin, J., additional, Whiteley, C., additional, Bennett, D., additional, Ostermann, M., additional, Gjyzari, A., additional, Thereska, N., additional, Koroshi, A., additional, Barbullushi, M., additional, Kodra, S., additional, Idrizi, A., additional, Strakosha, A., additional, Petrela, E., additional, Lemmich Smith, J., additional, Klimenko, A., additional, Tuykhmenev, E., additional, Villevalde, S., additional, Kobalava, Z., additional, Avdoshina, S., additional, Tyukhmenev, E., additional, Efremovtseva, M., additional, Hayashi, H., additional, Suzuki, S., additional, Kataoka, K., additional, Kondoh, Y., additional, Taniguchi, H., additional, Sugiyama, D., additional, Nishimura, K., additional, Sato, W., additional, Maruyama, S., additional, Matsuo, S., additional, Yuzawa, Y., additional, Geraldine, D., additional, Muriel, F., additional, Alexandre, H., additional, Eric, R., additional, Fu, P., additional, Pozzato, M., additional, Ferrari, F., additional, Cecere, P., additional, Mesiano, P., additional, Vallero, A., additional, Livigni, S., additional, Quarello, F., additional, Hudier, L., additional, Decaux, O., additional, Haddj-Elmrabet, A., additional, Mandart, L., additional, Lino-Daniel, M., additional, Bridoux, F., additional, Renaudineau, E., additional, Sawadogo, T., additional, Le Pogamp, P., additional, Vigneau, C., additional, Famee, D., additional, Koo, H. M., additional, Oh, H. J., additional, Han, S. H., additional, Choi, K. H., additional, Kang, S.-W., additional, Mehdi, M., additional, Nicolas, M., additional, Mariat, C., additional, Shah, P., additional, Kute, V. B., additional, Vanikar, A., additional, Gumber, M., additional, Patel, H., additional, Trivedi, H., additional, Manetos, C., additional, Poulaki, S., additional, Tripodaki, E.-S., additional, Papastylianou, A., additional, Routsi, C., additional, Uchida, K., additional, Kensuke, U., additional, Yamagata, K., additional, Saitou, C., additional, Okada, M., additional, Chita, G., additional, Davies, M., additional, Veriawa, Y., additional, Naicker, S., additional, Mukhopadhyay, P., additional, Mukherjee, D., additional, Mishra, R., additional, Kar, M., additional, Zickler, D., additional, Wesselmann, H., additional, Schindler, R., additional, Gutierrez*, E., additional, Egido, J., additional, Rubio-Navarro, A., additional, Buendia, I., additional, Blanco-Colio, L. M., additional, Toldos, O., additional, Manzarbeitia, F., additional, De Lorenzo, A., additional, Sanchez, R., additional, Praga^, M., additional, Moreno^, J. A., additional, Kim, M. Y., additional, Kang, N. R., additional, Jang, H. R., additional, Lee, J. E., additional, Huh, W., additional, Kim, Y.-G., additional, Kim, D. J., additional, Hong, S.-C., additional, Kim, J.-S., additional, Oh, H. Y., additional, Okamoto, T., additional, Kamata, K., additional, Naito, S., additional, Tazaki, H., additional, Kan, S., additional, Anne-Kathrin, L.-G., additional, Matthias, K., additional, Speer, T., additional, Andreas, L., additional, Heinrich, G., additional, Thomas, V., additional, Poppleton, A., additional, Danilo, F., additional, Lai, C.-F., additional, Wu, V.-C., additional, Shiao, C.-C., additional, Huang, T.-M., additional, Wu, K.-D., additional, Bedford, M., additional, Farmer, C., additional, Irving, J., additional, Stevens, P., additional, Patera, F., additional, Mattozzi, F., additional, Battistoni, S., additional, Fagugli, R. M., additional, Park, M. Y., additional, Choi, S. J., additional, Kim, J. G., additional, Hwang, S. D., additional, Xie, H., additional, Chen, H., additional, Xu, S., additional, He, Q., additional, Liu, J., additional, Hu, W., additional, Liu, Z., additional, Dalboni, M., additional, Blaya, R., additional, Quinto, B. M., additional, Narciso, R., additional, Oliveira, M., additional, Monte, J., additional, Durao, M., additional, Cendoroglo, M., additional, Batista, M., additional, Hanemann, A. L., additional, Liborio, A., additional, Martins, A., additional, Pinheiro, M. C. C., additional, Meneses, G., additional, De Paula Pessoa, R., additional, Sousa, M., additional, Bezerra, F. S. M., additional, Albuquerque, P. L. M. M., additional, Lima, J. B., additional, Lima, C. B., additional, Veras, M. D. S. B., additional, Nemoto Matsui, T., additional, Totoli, C., additional, Cruz Andreoli, M. C., additional, Vilela Coelho, M. P., additional, Guimaraes de Souza, N. K., additional, Ammirati, A. L., additional, De Carvalho Barreto, F., additional, Ferraz Neto, B.-H., additional, Fortunato Cardoso Dos Santos, B., additional, Abraham, A., additional, Abraham, G., additional, Mathew, M., additional, Duarte, P. M. A., additional, Duarte, F. B., additional, Barros, E. M., additional, Castro, F. Q. S., additional, Palomba, H., additional, Castro, I., additional, Sousa, S. R., additional, Jesus, A. N., additional, Romano, T., additional, Burdmann, E., additional, Yu, L., additional, Kwon, S. H., additional, You, J. Y., additional, Hyun, Y. K., additional, Woo, S. A., additional, Jeon, J. S., additional, Noh, H. J., additional, Han, D. C., additional, Tozija, L., additional, Petronievic, Z., additional, Selim, G., additional, Nikolov, I., additional, Stojceva-Taneva, O., additional, Cakalaroski, K., additional, Lukasz, A., additional, Beneke, J., additional, Menne, J., additional, Schiffer, M., additional, Polanco, N., additional, Hernandez, E., additional, Gutierrez, E., additional, Gutierrez Millet, V., additional, Gonzalez Monte, E., additional, Morales, E., additional, Praga, M., additional, Francisco Javier, L., additional, Nuria, G.-F., additional, Jose Maria, M.-G., additional, Bes Rastrollo, M., additional, Angioi, A., additional, Conti, M., additional, Cao, R., additional, Atzeni, A., additional, Pili, G., additional, Matta, V., additional, Murgia, E., additional, Melis, P., additional, Binda, V., additional, Pani, A., additional, Thome*, F., additional, Leusin, F., additional, Barros, E., additional, Morsch, C., additional, Balbinotto, A., additional, Pilla, C., additional, Premru, V., additional, Buturovic-Ponikvar, J., additional, Ponikvar, R., additional, Marn-Pernat, A., additional, Knap, B., additional, Kovac, J., additional, Gubensek, J., additional, Kersnic, B., additional, Krnjak, L., additional, Prezelj, M., additional, Granatova, J., additional, Havrda, M., additional, Hruskova, Z., additional, Kratka, K., additional, Remes, O., additional, Mokrejsova, M., additional, Bolkova, M., additional, Lanska, V., additional, Rychlik, I., additional, Uniacke, M. D., additional, Lewis, R. J., additional, Harris, S., additional, Roderick, P., additional, Martin, N., additional, Ulrich, K., additional, Jan, B., additional, Jorn, B., additional, Reinhard, B., additional, Jan, K., additional, Hermann, H., additional, Meyer Tobias, F., additional, Leyla, R., additional, Schmidt Bernhard, M. W., additional, Harald, S., additional, Jurgen, S., additional, Tanja, K., additional, Mario, S., additional, Sang Hi, E., additional, Claus, M., additional, Frank, V., additional, Aleksej, S., additional, Sengul, S., additional, Robert, S., additional, Karin, W., additional, Feikah, G., additional, Menne Tobias, F., additional, Meyer Tobias, N., additional, Beutel, G., additional, Fleig, S., additional, Steinhoff, J., additional, Meyer, T., additional, Hafer, C., additional, Bramstedt, J., additional, Busch, V., additional, Vischedyk, M., additional, Kuhlmann, U., additional, Ries, W., additional, Mitzner, S., additional, Mees, S., additional, Stracke, S., additional, Nurnberger, J., additional, Gerke, P., additional, Wiesner, M., additional, Sucke, B., additional, Abu-Tair, M., additional, Kribben, A., additional, Klause, N., additional, Merkel, F., additional, Schnatter, S., additional, Dorresteijn, E., additional, Samuelsson, O., additional, Brunkhorst, R., additional, Stec-Hus Registry, G., additional, Reising, A., additional, Bange, F.-C., additional, Hiss, M., additional, Vetter, F., additional, Bode-Boger, S. M., additional, Martens-Lobenhoffer, J., additional, Schmidt, B. M. W., additional, Kielstein, J. T., additional, Shin, H. S., additional, Jung, Y. S., additional, and Rim, H., additional
- Published
- 2012
- Full Text
- View/download PDF
16. Albumin-binding capacity (ABiC) is reduced in patients with chronic kidney disease along with an accumulation of protein-bound uraemic toxins
- Author
-
Klammt, S., primary, Wojak, H.-J., additional, Mitzner, A., additional, Koball, S., additional, Rychly, J., additional, Reisinger, E. C., additional, and Mitzner, S., additional
- Published
- 2011
- Full Text
- View/download PDF
17. PGI12 THE COSTS OF ACUTE-ON-CHRONIC LIVER FAILURE—A BOTTOM-UP ANALYSIS BASED ON INDIVIDUAL PATIENT DATA
- Author
-
Hessel, FP, primary, Mitzner, S, additional, and Wasem, J, additional
- Published
- 2005
- Full Text
- View/download PDF
18. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis mars: Results of a prospective, randomized, controlled clinical trial
- Author
-
MITZNER, S, primary, STANGE, J, additional, KLAMMT, S, additional, RISLER, T, additional, ERLEY, C, additional, BADER, B, additional, BERGER, E, additional, LAUCHART, W, additional, PESZYNSKI, P, additional, and FREYTAG, J, additional
- Published
- 2000
- Full Text
- View/download PDF
19. CELL-BASED PHAGOCYTOSIS ASSIST - RESULTS OF AN EX-VIVO ANIMAL MODEL OF SEPSIS
- Author
-
Sauer, M., primary, Freytag, J., additional, Oberender, F., additional, Altrichter, J., additional, Stange, J., additional, Nizze, H., additional, Kreutzer, H., additional, Schmidt, R., additional, and Mitzner, S., additional
- Published
- 1999
- Full Text
- View/download PDF
20. Targeted chemotherapy with encapsulated, genetically modified cells engineered to produce CYP2B1, an ifosfamide converting enzyme
- Author
-
Müller, P., primary, Karle, P., additional, Jesnowski, R., additional, Saller, Robert, additional, Mitzner, S., additional, Stange, J., additional, Liebe, S., additional, Salmons, B., additional, Günzburg, W.H., additional, and Löhr, M., additional
- Published
- 1998
- Full Text
- View/download PDF
21. 4
- Author
-
Sauer, M., primary, Frevtag, J., additional, Oberender, F., additional, Altrichter, J., additional, Schmidt, R., additional, and Mitzner, S., additional
- Published
- 1998
- Full Text
- View/download PDF
22. Autonomic neuropathy in dialysis patients - investigations with a new symptom score (COMPASS 31).
- Author
-
Schramm CV, Schramm MC, Trautner M, Hinz M, and Mitzner S
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Diabetic Neuropathies diagnosis, Diabetic Neuropathies etiology, Renal Dialysis adverse effects, Autonomic Nervous System Diseases etiology, Autonomic Nervous System Diseases diagnosis
- Abstract
Background: Symptoms of autonomic neuropathy (AN) are common in patients with diabetes and advanced renal disease. As yet different domains of autonomic neuropathy cannot be detected by a singular laboratory or invasive test. COMPASS 31, a new self-assessment test, has shown reliable results not only in cardiac autonomic neuropathy but also in different sub-domains when judging manifestation of AN by scores., Methods: One hundred eighty-three patients with or without diabetes were enrolled, one hundred nineteen of them were treated with permanent dialysis therapy (HD), sixty-four patients served as controls (eGFR > 60 ml/min.) Using COMPASS 31 different symptoms of AN were assessed (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder, pupillomotor changes) and transferred into AN-scores., Results: AN was more pronounced in dialysis patients compared with controls (AN-score 27,5 vs. 10,0; p < 0,01). These differences were present also in every sub-domain of AN (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder, pupillomotor changes; p < 0,05 for all sub-domains). In diabetic patients there was a strong correlation between symptoms of AN and diabetes duration (correlation coefficient r = 0,45, p < 0,001). Current glycemic control (HbA1c), body mass index (BMI), sex, and height had no influence on AN when comparing dialysis patients and controls. C-reactive protein (CRP) showed a positive linear correlation with AN-scores (correlation coefficient r = 0,21; p < 0,05)., Conclusion: Symptoms of AN are more pronounced in dialysis patients not only in total but also in all different domains of neuropathic changes. Longlasting diabetic disease promotes development of AN, as duration of diabetes was positively correlated with AN. Future longitudinal studies might help to identify the high cardiovascular and mortality risk in dialysis patients by the easy-to-use COMPASS 31 without need of invasive and time-spending methods for diagnosing AN., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
23. Hemoadsorption therapy for myoglobin removal in rhabdomyolysis: consensus of the hemoadsorption in rhabdomyolysis task force.
- Author
-
Forni L, Aucella F, Bottari G, Büttner S, Cantaluppi V, Fries D, Kielstein J, Kindgen-Milles D, Krenn C, Kribben A, Meiser A, Mitzner S, Ostermann M, Premuzic V, Rolfes C, Scharf C, Schunk S, Molnar Z, and Zarbock A
- Subjects
- Humans, Hemadsorption, Delphi Technique, Consensus, Rhabdomyolysis therapy, Myoglobin blood
- Abstract
Background: Rhabdomyolysis describes a syndrome characterized by muscle necrosis and the subsequent release of creatine kinase and myoglobin into the circulation. Myoglobin elimination with extracorporeal hemoadsorption has been shown to effectively remove myoglobin from the circulation. Our aim was to provide best practice consensus statements developed by the Hemoadsorption in Rhabdomyolysis Task Force (HRTF) regarding the use of hemadsorption for myoglobin elimination., Methods: A systematic literature search was performed until 11th of January 2023, after which the Rhabdomyolysis RTF was assembled comprising international experts from 6 European countries. Online conferences were held between 18th April - 4th September 2023, during which 37 consensus questions were formulated and using the Delphi process, HRTF members voted online on an anonymised platform. In cases of 75 to 90% agreement a second round of voting was performed., Results: Using the Delphi process on the 37 questions, strong consensus (> 90% agreement) was achieved in 12, consensus (75 to 90% agreement) in 10, majority (50 to 74%) agreement in 13 and no consensus (< 50% agreement) in 2 cases. The HRTF formulated the following recommendations: (1) Myoglobin contributes to the development of acute kidney injury; (2) Patients with myoglobin levels of > 10,000 ng/ml should be considered for extracorporeal myoglobin removal by hemoadsorption; (3) Hemoadsorption should ideally be started within 24 h of admission; (4) If myoglobin cannot be measured then hemoadsorption may be indicated based on clinical picture and creatinine kinase levels; (5) Cartridges should be replaced every 8-12 h until myoglobin levels < 10,000 ng/ml; (6) In patients with acute kidney injury, hemoadsorption can be discontinued before dialysis is terminated and should be maintained until the myoglobin concentration values are consistently < 5000 ng/ml., Conclusions: The current consensus of the HRTF support that adjuvant hemoadsorption therapy in severe rhabdomyolysis is both feasible and safe and may be an effective method to reduce elevated circulating levels of myoglobin., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
24. The Utility of Miniaturized Adsorbers in Exploring the Cellular and Molecular Effects of Blood Purification: A Pilot Study with a Focus on Immunoadsorption in Multiple Sclerosis.
- Author
-
Körtge A, Breitrück A, Doß S, Hofrichter J, Nelz SC, Krüsemann H, Wasserkort R, Fitzner B, Hecker M, Mitzner S, and Zettl UK
- Subjects
- Humans, Pilot Projects, Plasma, Neutrophils, Leukocytes, Multiple Sclerosis
- Abstract
Immunoadsorption (IA) has proven to be clinically effective in the treatment of steroid-refractory multiple sclerosis (MS) relapses, but its mechanism of action remains unclear. We used miniaturized adsorber devices with a tryptophan-immobilized polyvinyl alcohol (PVA) gel sorbent to mimic the IA treatment of patients with MS in vitro. The plasma was screened before and after adsorption with regard to disease-specific mediators, and the effect of the IA treatment on the migration of neutrophils and the integrity of the endothelial cell barrier was tested in cell-based models. The in vitro IA treatment with miniaturized adsorbers resulted in reduced plasma levels of cytokines and chemokines. We also found a reduced migration of neutrophils towards patient plasma treated with the adsorbers. Furthermore, the IA-treated plasma had a positive effect on the endothelial cell barrier's integrity in the cell culture model. Our findings suggest that IA results in a reduced infiltration of cells into the central nervous system by reducing leukocyte transmigration and preventing blood-brain barrier breakdown. This novel approach of performing in vitro blood purification therapies on actual patient samples with miniaturized adsorbers and testing their effects in cell-based assays that investigate specific hypotheses of the pathophysiology provides a promising platform for elucidating the mechanisms of action of those therapies in various diseases.
- Published
- 2024
- Full Text
- View/download PDF
25. Adjunctive Hemoadsorption Therapy with CytoSorb in Patients with Septic/Vasoplegic Shock: A Best Practice Consensus Statement.
- Author
-
Mitzner S, Kogelmann K, Ince C, Molnár Z, Ferrer R, and Nierhaus A
- Abstract
A dysregulated host response is a common feature in critically ill patients due to both infectious and non-infectious origins that can lead to life-threatening organ dysfunction, which is still the primary cause of death in intensive care units worldwide. In its course, pathologic, unregulated levels of inflammatory mediators are often released into the circulation, a phenomenon also referred to as a "cytokine storm". To date, there are no approved therapies to modulate the excessive immune response and limit hyperinflammation with the goal of preventing related organ failure and death. In this context, extracorporeal blood purification therapies aiming at the alteration of the host inflammatory response through broad-spectrum, non-selective removal of inflammatory mediators have come into focus. A novel hemoadsorption device (CytoSorb
® , CytoSorbents Inc., Princeton, NJ, USA) has shown promising results in patients with hyperinflammation from various origins. Although a significant body of literature exists, there is ongoing research to address many important remaining questions, including the optimal selection of patient groups who might benefit the most, optimal timing for therapy initiation, optimal schedule for adsorber exchanges and therapy duration, as well as an investigation into the potential removal of concomitant antibiotics and other medications. In this review, we discuss the existing evidence and provide a consensus-based best practice guidance for CytoSorb® hemoadsorption therapy in patients with vasoplegic shock.- Published
- 2023
- Full Text
- View/download PDF
26. Exploring Albumin Functionality Assays: A Pilot Study on Sepsis Evaluation in Intensive Care Medicine.
- Author
-
Klinkmann G, Waterstradt K, Klammt S, Schnurr K, Schewe JC, Wasserkort R, and Mitzner S
- Subjects
- Humans, Pilot Projects, Critical Illness, Prospective Studies, Albumins, Critical Care, Shock, Septic diagnosis, Sepsis diagnosis
- Abstract
Human serum albumin (HSA) as the most abundant plasma protein carries multifunctional properties. A major determinant of the efficacy of albumin relies on its potent binding capacity for toxins and pharmaceutical agents. Albumin binding is impaired in pathological conditions, affecting its function as a molecular scavenger. Limited knowledge is available on the functional properties of albumin in critically ill patients with sepsis or septic shock. A prospective, non-interventional clinical trial assessed blood samples from 26 intensive care patients. Albumin-binding capacity (ABiC) was determined by quantifying the unbound fraction of the fluorescent marker, dansyl sarcosine. Electron paramagnetic resonance fatty acid spin-probe evaluated albumin's binding and detoxification efficiencies. Binding efficiency (BE) reflects the strength and amount of bound fatty acids, and detoxification efficiency (DTE) indicates the molecular flexibility of patient albumin. ABiC, BE, and DTE effectively differentiated control patients from those with sepsis or septic shock (AUROC > 0.8). The diagnostic performance of BE showed similarities to procalcitonin. Albumin functionality correlates with parameters for inflammation, hepatic, or renal insufficiency. Albumin-binding function was significantly reduced in critically ill patients with sepsis or septic shock. These findings may help develop patient-specific algorithms for new diagnostic and therapeutic approaches.
- Published
- 2023
- Full Text
- View/download PDF
27. Imaging Predictors of Left Ventricular Functional Recovery after Reperfusion Therapy of ST-Elevation Myocardial Infarction Assessed by Cardiac Magnetic Resonance.
- Author
-
Virbickiene A, Lapinskas T, Garlichs CD, Mattecka S, Tanacli R, Ries W, Torzewski J, Heigl F, Pfluecke C, Darius H, Ince H, Nordbeck P, Butter C, Schuster A, Mitzner S, Dobiliene O, Sheriff A, and Kelle S
- Abstract
Background: Left ventricular global longitudinal strain (LV GLS) is a superior predictor of adverse cardiac events in patients with myocardial infarction and heart failure. We investigated the ability of morphological features of infarcted myocardium to detect acute left ventricular (LV) dysfunction and predict LV functional recovery after three months in patients with acute ST-segment elevation myocardial infarction (STEMI)., Methods: Sixty-six STEMI patients were included in the C-reactive protein (CRP) apheresis in Acute Myocardial Infarction Study (CAMI-1). LV ejection fraction (LVEF), LV GLS, LV global circumferential strain (LV GCS), infarct size (IS), area-at-risk (AAR), and myocardial salvage index (MSI) were assessed by CMR 5 ± 3 days (baseline) and 12 ± 2 weeks after (follow-up) the diagnosis of first acute STEMI., Results: Significant changes in myocardial injury parameters were identified after 12 weeks of STEMI diagnosis. IS decreased from 23.59 ± 11.69% at baseline to 18.29 ± 8.32% at follow-up ( p < 0.001). AAR and MVO also significantly reduced after 12 weeks. At baseline, there were reasonably moderate correlations between IS and LVEF ( r = -0.479, p < 0.001), LV GLS ( r = 0.441, p < 0.001) and LV GCS ( r = 0.396, p = 0.001) as well as between AAR and LVEF ( r = -0.430, p = 0.003), LV GLS ( r = 0.501, p < 0.001) and weak with LV GCS ( r = 0.342, p = 0.020). At follow-up, only MSI and change in LV GCS over time showed a weak but significant correlation ( r = -0.347, p = 0.021). Patients with larger AAR at baseline improved more in LVEF ( p = 0.019) and LV GLS ( p = 0.020) but not in LV GCS., Conclusion: The CMR tissue characteristics of myocardial injury correlate with the magnitude of LV dysfunction during the acute stage of STEMI. AAR predicts improvement in LVEF and LV GLS, while MSI is a sensitive marker of LV GCS recovery at three months follow-up after STEMI.
- Published
- 2023
- Full Text
- View/download PDF
28. Impact of Albumin Binding Function on Pharmacokinetics and Pharmacodynamics of Furosemide.
- Author
-
Klinkmann G, Klammt S, Jäschke M, Henschel J, Gloger M, Reuter DA, and Mitzner S
- Subjects
- Humans, Prospective Studies, Albumins, Kidney, Furosemide pharmacology, Furosemide therapeutic use, Diuretics pharmacology, Diuretics therapeutic use
- Abstract
Background and Objectives: Albumin binding of the loop diuretic furosemide forms the basis for its transport to the kidney and subsequent tubular secretion, which is a prerequisite for its therapeutic effects. Accordingly, high albumin concentrations should result in higher efficacy of furosemide. However, study results on the combination of furosemide in conjunction with albumin, and on the efficacy of furosemide in hypoalbuminemia, did not confirm this hypothesis. The aim of this study was to determine the efficacy of furosemide not only in relation to albumin concentration, but also taking albumin function into account. Materials and Methods: In a prospective and non-interventional clinical observational trial, blood and urine samples from 50 intensive care patients receiving continuous intravenous furosemide therapy were evaluated. Albumin binding capacity (ABiC) determination allowed conclusions to be drawn about the binding site-specific loading state of albumin, by quantifying the unbound fraction of the fluorescent marker dansylsarcosine. In addition, assessment of the total concentration of furosemide in plasma and urine, as well as the concentration of free furosemide fraction in plasma, was performed by HPLC−MS. The efficacy of furosemide was evaluated by the ratio of urine excretion to fluid intake. Results: In patients with an ABiC ≥ 60% free furosemide fraction was significantly lower compared to patients with a lower ABiC (p < 0.001), urinary furosemide concentration was higher (p = 0.136), and a significantly higher proportion of infused furosemide was excreted renally (p = 0.010). ABiC was positively correlated (r = 0.908, p = 0.017) with increase in the urine excretion to fluid input ratio after initiation of furosemide therapy. Conclusions: ABiC could serve as a marker for individual response to furosemide and could be used to generate patient-specific therapeutic regimens. In view of the relatively low number of patients in this study, the relationship between furosemide efficacy and albumin function should be investigated in larger studies in the future.
- Published
- 2022
- Full Text
- View/download PDF
29. Extracorporeal immune cell therapy of sepsis: ex vivo results.
- Author
-
Klinkmann G, Wild T, Heskamp B, Doss F, Doss S, Arseniev L, Aleksandrova K, Sauer M, Reuter DA, Mitzner S, and Altrichter J
- Abstract
Background: Immune cell dysfunction plays a central role in sepsis-associated immune paralysis. The transfusion of healthy donor immune cells, i.e., granulocyte concentrates (GC) potentially induces tissue damage via local effects of neutrophils. Initial clinical trials using standard donor GC in a strictly extracorporeal bioreactor system for treatment of septic shock patients already provided evidence for beneficial effects with fewer side effects, by separating patient and donor immune cells using plasma filters. In this ex vivo study, we demonstrate the functional characteristics of a simplified extracorporeal therapy system using purified granulocyte preparations., Methods: Purified GC were used in an immune cell perfusion model prefilled with human donor plasma simulating a 6-h treatment. The extracorporeal circuit consisted of a blood circuit and a plasma circuit with 3 plasma filters (PF). PF1 is separating the plasma from the patient's blood. Plasma is then perfused through PF2 containing donor immune cells and used in a dead-end mode. The filtrated plasma is finally retransfused to the blood circuit. PF3 is included in the plasma backflow as a redundant safety measure. The donor immune cells are retained in the extracorporeal system and discarded after treatment. Phagocytosis activity, oxidative burst and cell viability as well as cytokine release and metabolic parameters of purified GCs were assessed., Results: Cells were viable throughout the study period and exhibited well-preserved functionality and efficient metabolic activity. Course of lactate dehydrogenase and free hemoglobin concentration yielded no indication of cell impairment. The capability of the cells to secret various cytokines was preserved. Of particular interest is equivalence in performance of the cells on day 1 and day 3, demonstrating the sustained shelf life and performance of the immune cells in the purified GCs., Conclusion: Results demonstrate the suitability of a simplified extracorporeal system. Furthermore, granulocytes remain viable and highly active during a 6-h treatment even after storage for 3 days supporting the treatment of septic patients with this system in advanced clinical trials., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
30. Phosphate restriction using a processed clay mineral reduces vascular pathologies and microalbuminuria in rats with chronic renal failure.
- Author
-
Hofrichter J, Sempert K, Kerkhoff C, Breitrück A, Wasserkort R, and Mitzner S
- Subjects
- Albuminuria complications, Animals, Clay, Female, Humans, Male, Minerals, Phosphates, Rats, Kidney Failure, Chronic complications, Renal Insufficiency, Chronic complications
- Abstract
Background: The progression of chronic kidney disease (CKD) is associated with an increasing risk of cardiovascular morbidity and mortality due to elevated serum phosphate levels. Besides low phosphate diets and hemodialysis, oral phosphate binders are prescribed to treat hyperphosphatemia in CKD patients. This study reports on a processed clay mineral as a novel and efficient phosphate sorbent with comparable efficacy of a clinically approved phosphate binder., Methods: 5/6 nephrectomized rats, which develop chronic renal failure (CRF), received a high phosphate and calcium diet supplemented with either a processed Montmorillonite-Illite clay mineral (pClM) or lanthanum carbonate (LaC) for 12 weeks. Levels of plasma uremic toxins, glomerular filtration rates and microalbuminuria were determined and the histomorphology of blood vessels and smooth muscle cells was analyzed., Results: 5/6 nephrectomy induced an increase in plasma uremic toxins levels and progressive proteinuria. Treatment of CRF rats with pClM decreased observed vascular pathologies such as vascular fibrosis, especially in coronary vessels. The transition of vascular smooth muscle cells from a contractile to a secretory phenotype was delayed. Moreover, pClM administration resulted in decreased blood creatinine and urea levels, and increased glomerular filtration rates, reduced microalbuminuria and eventually the mortality rate in CRF rats., Conclusion: Our study reveals pClM as a potent phosphate binding agent with beneficial impacts on pathophysiological processes in an animal model of CKD. pClM effectively attenuates the progression of vascular damage and loss of renal function which are the most severe consequences of chronic renal failure., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
31. Smectite as a Preventive Oral Treatment to Reduce Clinical Symptoms of DSS Induced Colitis in Balb/c Mice.
- Author
-
Breitrück A, Weigel M, Hofrichter J, Sempert K, Kerkhoff C, Mohebali N, Mitzner S, Hain T, and Kreikemeyer B
- Subjects
- Administration, Oral, Animals, Bacteria drug effects, Bacteria genetics, Bacteria isolation & purification, Body Weight drug effects, Colitis chemically induced, Colitis metabolism, Colitis microbiology, DNA, Bacterial genetics, DNA, Ribosomal genetics, Feces microbiology, Male, Mice, Inbred BALB C, Phylogeny, RNA, Ribosomal, 16S genetics, Sequence Analysis, DNA, Severity of Illness Index, Silicates pharmacology, Tight Junction Proteins metabolism, Treatment Outcome, Mice, Bacteria classification, Colitis drug therapy, Dextran Sulfate adverse effects, Microbiota drug effects, Silicates administration & dosage
- Abstract
Natural smectites have demonstrated efficacy in the treatment of diarrhea. The present study evaluated the prophylactic effect of a diosmectite (FI5pp) on the clinical course, colon damage, expression of tight junction (TJ) proteins and the composition of the gut microbiota in dextran sulfate sodium (DSS) colitis. Diosmectite was administered daily to Balb/c mice from day 1 to 7 by oral gavage, followed by induction of acute DSS-colitis from day 8 to 14 ("Control", n = 6; "DSS", n = 10; "FI5pp + DSS", n = 11). Mice were sacrificed on day 21. Clinical symptoms (body weight, stool consistency and occult blood) were checked daily after colitis induction. Colon tissue was collected for histological damage scoring and quantification of tight junction protein expression. Stool samples were collected for microbiome analysis. Our study revealed prophylactic diosmectite treatment attenuated the severity of DSS colitis, which was apparent by significantly reduced weight loss ( p = 0.022 vs. DSS), disease activity index ( p = 0.0025 vs. DSS) and histological damage score ( p = 0.023 vs. DSS). No significant effects were obtained for the expression of TJ proteins (claudin-2 and claudin-3) after diosmectite treatment. Characterization of the microbial composition by 16S amplicon NGS showed that diosmectite treatment modified the DSS-associated dysbiosis. Thus, diosmectites are promising candidates for therapeutic approaches to target intestinal inflammation and to identify possible underlying mechanisms of diosmectites in further studies.
- Published
- 2021
- Full Text
- View/download PDF
32. C-Reactive Protein Apheresis as Anti-inflammatory Therapy in Acute Myocardial Infarction: Results of the CAMI-1 Study.
- Author
-
Ries W, Torzewski J, Heigl F, Pfluecke C, Kelle S, Darius H, Ince H, Mitzner S, Nordbeck P, Butter C, Skarabis H, Sheriff A, and Garlichs CD
- Abstract
Background: C-reactive protein (CRP) is a well-known marker of inflammation. It is less known that CRP mediates tissue damage in acute myocardial infarction (AMI) thus potentially worsening prognosis. A newly developed specific CRP adsorber allows efficient lowering of CRP levels and may improve survival. Objectives: Aim of this multi-center, controlled, non-randomized first-in-man CRP apheresis in Acute Myocardial Infarction study (CAMI-1) was to investigate the relationship between CRP levels (CRP gradient), myocardial infarct size and function as well as safety and efficacy of CRP apheresis in the setting of acute ST-segment Elevation Myocardial Infarction (STEMI) in humans. Methods: Eighty-three patients (45 apheresis, 38 controls) were recruited. CRP apheresis was performed 24 ± 12, 48 ± 12, and optionally 72 ± 12 h after onset of symptoms. First aphereses were performed at a median CRP concentration of 23.0 mg/L (range 9-279). In each apheresis session, 5,900 ± 400 mL plasma was processed via peripheral venous access. Primary study endpoint was a reduction in myocardial infarct size after STEMI as determined by cardiovascular magnetic resonance (CMR). Results: In controls, the CRP concentration significantly correlated with infarct size ( p = 0.002) and decreased myocardial function ( p ≤ 0.001). The CRP concentration in apheresis patients did not correlate with infarct size ( p = 0.66) or left ventricular (LV) function ( p = 0.79) and global strains and therefore significantly differed from controls ( p = 0.03 and p = 0.002). Three major adverse cardiac events occurred in the control group after 12 months, none occurred in the apheresis group. Mean CRP depletion achieved over all apheresis procedures was 53.0 ± 15.1%. Apheresis sessions were well-tolerated. Reduced infarct size in the apheresis group compared to the control group (primary endpoint) was not achieved according to the original statistical analysis plan. Taking into account the individual CRP levels, however, revealed significant results. Modifications of the analysis plan were introduced in order to recruit a sufficient number of patients. Conclusions: This pilot study in humans reveals a correlation between CRP concentration and myocardial infarct size. CRP concentrations in STEMI can effectively be reduced by CRP apheresis without relevant side effects. CRP apheresis has the potential to interfere with deleterious aspects of STEMI. By lowering CRP levels, it resulted in the loss of correlation of CRP concentrations with myocardial infarct sizes as well as LV function. These results encourage a larger, randomized clinical trial. Clinical Trial Registration: https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00008988, DRKS00008988., Competing Interests: AS was a founder and is shareholder and managing director of Pentracor GmbH. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Ries, Torzewski, Heigl, Pfluecke, Kelle, Darius, Ince, Mitzner, Nordbeck, Butter, Skarabis, Sheriff and Garlichs.)
- Published
- 2021
- Full Text
- View/download PDF
33. Efficacy and safety of liver support devices in acute and hyperacute liver failure: a systematic review and network meta-analysis.
- Author
-
Kanjo A, Ocskay K, Gede N, Kiss S, Szakács Z, Párniczky A, Mitzner S, Stange J, Hegyi P, and Molnár Z
- Subjects
- Bayes Theorem, Hemoperfusion instrumentation, Hemoperfusion methods, Humans, Liver physiopathology, Liver Transplantation instrumentation, Liver Transplantation methods, Network Meta-Analysis, Randomized Controlled Trials as Topic, Liver Failure, Acute therapy, Prostheses and Implants adverse effects
- Abstract
Acute liver failure (ALF) is a potentially life-threatening condition. Liver support therapies can be applied as a bridging-to-transplantation or bridging-to-recovery; however, results of clinical trials are controversial. Our aim was to compare liver support systems in acute and hyperacute liver failure with network meta-analysis. After systematic search, randomized controlled trials (RCT) comparing liver support therapies in adults with acute or hyperacute liver failure were included. In-hospital mortality was the primary outcome, the secondary outcomes were hepatic encephalopathy and mortality-by-aetiology. A Bayesian-method was used to perform network meta-analysis and calculate surface under the cumulative ranking curve (SUCRA) values to rank interventions. Eleven RCTs were included. BioLogic-DT and molecular adsorbent recirculating system (MARS) resulted in the lowest mortality (SUCRAs: 76% and 73%, respectively). In non-paracetamol-poisoned patients, BioLogic-DT, charcoal hemoperfusion and MARS may be equally efficient regarding mortality (SUCRAs: 53%, 52% and 52%, respectively). Considering hepatic encephalopathy, extracorporeal liver assist device (ELAD) may be the most effective option (SUCRA: 78%). However, in pairwise meta-analysis, there were no statistically significant differences between the interventions in the outcomes. In conclusion, MARS therapy seems to be the best available option in reducing mortality. Further research is needed on currently available and new therapeutic modalities. (CRD42020160133).
- Published
- 2021
- Full Text
- View/download PDF
34. Uncertainty in the impact of liver support systems in acute-on-chronic liver failure: a systematic review and network meta-analysis.
- Author
-
Ocskay K, Kanjo A, Gede N, Szakács Z, Pár G, Erőss B, Stange J, Mitzner S, Hegyi P, and Molnár Z
- Abstract
Background: The role of artificial and bioartificial liver support systems in acute-on-chronic liver failure (ACLF) is still controversial. We aimed to perform the first network meta-analysis comparing and ranking different liver support systems and standard medical therapy (SMT) in patients with ACLF., Methods: The study protocol was registered with PROSPERO (CRD42020155850). A systematic search was conducted in five databases. We conducted a Bayesian network meta-analysis of randomized controlled trials assessing the effect of artificial or bioartificial liver support systems on survival in patients with ACLF. Ranking was performed by calculating the surface under cumulative ranking (SUCRA) curve values. The RoB2 tool and a modified GRADE approach were used for the assessment of the risk of bias and quality of evidence (QE)., Results: In the quantitative synthesis 16 trials were included, using MARS®, Prometheus®, ELAD®, plasma exchange (PE) and BioLogic-DT®. Overall (OS) and transplant-free (TFS) survival were assessed at 1 and 3 months. PE significantly improved 3-month OS compared to SMT (RR 0.74, CrI: 0.6-0.94) and ranked first on the cumulative ranking curves for both OS outcomes (SUCRA: 86% at 3 months; 77% at 1 month) and 3-month TFS (SUCRA: 87%) and second after ELAD for 1-month TFS (SUCRA: 76%). Other comparisons did not reach statistical significance. QE was moderate for PE concerning 1-month OS and both TFS outcomes. Other results were of very low certainty., Conclusion: PE seems to be the best currently available liver support therapy in ACLF regarding 3-month OS. Based on the low QE, randomized trials are needed to confirm our findings for already existing options and to introduce new devices.
- Published
- 2021
- Full Text
- View/download PDF
35. Relative incidence of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome in clinically suspected cases of thrombotic microangiopathy.
- Author
-
Schönermarck U, Ries W, Schröppel B, Pape L, Dunaj-Kazmierowska M, Burst V, Mitzner S, Basara N, Starck M, Schmidbauer D, Mellmann A, Dittmer R, Jeglitsch M, and Haas CS
- Abstract
Background: Data are lacking on the relative incidence of thrombotic thrombocytopenic purpura (TTP), haemolytic uraemic syndrome (HUS) caused by Shiga toxin-producing Escherichia coli (STEC) and atypical HUS (aHUS) in patients presenting with thrombotic microangiopathies (TMAs)., Methods: This was a prospective, cross-sectional, multicentre and non-interventional epidemiological study. Patients fulfilling criteria for TMAs (platelet consumption, microangiopathic haemolytic anaemia and organ dysfunction) were included in the study. The primary objective was to assess the relative incidence of TTP, STEC-HUS, aHUS and 'other' physician-defined diagnoses. The secondary objective was to develop an algorithm to predict a severe deficiency in ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity (≤10%) using routine laboratory parameters. A post hoc classification using the recent Kidney Disease: Improving Global Outcomes diagnostic criteria was then undertaken to further classify patient groups., Results: aHUS was diagnosed with a relative incidence of 61%, whereas TTP, STEC-HUS and 'other' were diagnosed in 13, 6 and 20% of patients, respectively. In the post hoc analysis, 27% of patients with a TMA were classified as 'primary aHUS' and 53% as 'secondary aHUS'. Multivariate analysis revealed that severe deficiency in ADAMTS13 activity (≤10%) was unlikely to underlie TMA if platelet and serum creatinine were above threshold values of 30 × 10
9 /L and 1.8 mg/dL, respectively (negative predictive value of 92.3 and 98.1, respectively, if one or both values were above the threshold)., Conclusions: In this study, aHUS was the most common single diagnosis among patients presenting with a TMA. In the absence of an ADAMTS13 activity result, platelet count and serum creatinine may aid in the differential diagnosis., (© The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA.)- Published
- 2019
- Full Text
- View/download PDF
36. Impaired Cell Viability and Functionality of Hepatocytes After Incubation With Septic Plasma-Results of a Second Prospective Biosensor Study.
- Author
-
Sauer M, Haubner C, Richter G, Ehler J, Mencke T, Mitzner S, Margraf S, Altrichter J, Doß S, and Nöldge-Schomburg G
- Abstract
Liver dysfunction (LD) and liver failure are associated with poor outcome in critically ill patients. In patients with severe sepsis or septic shock, LD occurred in nearly 19% of patients. An early diagnosis of LD at time of initial damage of the liver can lead to a better prognosis of these patients because an early start of therapy is possible. We performed a second prospective study with septic patients to test a new cell-based cytotoxicity device (biosensor) to evaluate clinical relevance for early diagnosis of LD and prognostic capacity. In the clinical study, 99 intensive care unit patients were included in two groups. From the patients of the septic group ( n = 51, SG), and the control (non-septic) group [ n = 49, control group (CG)] were drawn 20 ml blood at inclusion, after 3, and 7 days for testing with the biosensor. Patients' data were recorded for hospital survival, organ function, and demographic data, illness severity [acute physiology and chronic health evaluation (APACHE) II-, sepsis-related organ failure assessment (SOFA) scores], cytokines, circulating-free deoxyribonucleic acid/neutrophil-derived extracellular traps (cf-DNA/NETs), microbiological results, and pre-morbidity. For the developed cytotoxicity test, the human liver cell line HepG2/C3A was used. Patients' plasma was incubated in a microtiter plate assay with the test cells and after 6 days incubation the viability (trypan blue staining, XTT-test) and functionality (synthesis of albumin, cytochrome 1A2 activity) was analyzed. An impairment of viability and functionality of test cells was only seen in the SG compared with the CG. The plasma of non-survivors in the SG led to a more pronounced impairment of test cells than the plasma of survivors at inclusion. In addition, the levels of cf-DNA/NETs were significantly higher in the SG at inclusion, after 3, and after 7 days compared with the CG. The SG showed an in-hospital mortality of 24% and the values of bilirubin, APACHE II-, and SOFA scores were markedly higher at inclusion than in the CG. Hepatotoxicity of septic plasma was already detected with the liver cell-based biosensor at inclusion and also in the course of disease. The biosensor may be a tool for early diagnosis of LD in septic patients and may have prognostic relevance.
- Published
- 2018
- Full Text
- View/download PDF
37. Treatment of the First Acute Relapse Following Therapeutic Plasma Exchange in Formerly Glucocorticosteroid-Unresponsive Multiple Sclerosis Patients-A Multicenter Study to Evaluate Glucocorticosteroid Responsiveness.
- Author
-
Ehler J, Blechinger S, Rommer PS, Koball S, Mitzner S, Hartung HP, Leutmezer F, Sauer M, and Zettl UK
- Subjects
- Adolescent, Adrenal Cortex Hormones administration & dosage, Adult, Aged, Humans, Middle Aged, Multiple Sclerosis, Relapsing-Remitting therapy, Plasma Exchange methods, Adrenal Cortex Hormones therapeutic use, Multiple Sclerosis, Relapsing-Remitting drug therapy, Plasma Exchange adverse effects
- Abstract
Therapeutic options to treat multiple sclerosis (MS) relapses comprise glucocorticosteroids (GCS) as first-line and therapeutic plasma exchange (TPE) as second-line treatments in GCS-unresponsive patients. No guidelines exist for the treatment of another relapse following TPE. We retrospectively analyzed the responsiveness to GCS in a subsequent relapse following TPE in previously GCS-unresponsive MS patients. Thirty-seven patients with GCS-unresponsive MS relapses received TPE (relapse A). All patients developed another relapse after the completion of TPE and received GCS again (relapse B). The primary study endpoint was the clinical response to GCS and TPE. Marked improvement was defined as clinically significant improvement in function, moderate improvement as a definite change of symptoms without significant impact on function, no effect comprised unchanged symptoms, and deterioration a worsening of symptoms or new deficits. The secondary endpoint was an improvement in expanded disability status scale (EDSS) scoring. All patients were GCS-unresponsive during relapse A and received TPE. During GCS treatment of relapse B, marked improvement was observed in 10, moderate improvement in 24, and no effect in three patients. The EDSS decreased in 15 patients. GCS might remain the first-line relapse treatment following TPE in formerly GCS-unresponsive MS patients., Competing Interests: Sebastian Koball received speaker fees from Fresenius Medical Care, Gambro-Baxter and Miltenyi. Uwe K. Zettl and Fritz Leutmezer received speaker fees from Bayer Healthcare, Biogen Idec, Genzyme, Merck-Serono, Novartis and Teva. Hans-Peter Hartung has received fees for consulting, serving on steering committees and speaking at symposia from Bayer Healthcare, Baxter, Biogen, CSL Behring, Geneuro, Genzyme, Medimmune, Merck, Octapharma, Opexa, Receptos, Roche, and Teva with approval by the Rector of Heinrich-Heine-University. The remaining authors declare that there is no conflict of interest.
- Published
- 2017
- Full Text
- View/download PDF
38. Hepatotoxicity of Antimycotics Used for Invasive Fungal Infections: In Vitro Results.
- Author
-
Doß S, Potschka H, Doß F, Mitzner S, and Sauer M
- Subjects
- Anidulafungin, Caspofungin, Chemical and Drug Induced Liver Injury complications, Chemical and Drug Induced Liver Injury pathology, Echinocandins adverse effects, Fluconazole adverse effects, Hep G2 Cells, Hepatocytes pathology, Humans, Invasive Fungal Infections complications, Lipopeptides adverse effects, Liver pathology, Voriconazole adverse effects, Antifungal Agents adverse effects, Hepatocytes drug effects, Invasive Fungal Infections drug therapy, Liver drug effects
- Abstract
Purpose. Drug-induced liver injury (DILI) is the most common cause of liver injury and a serious clinical problem; antimycotics are involved in approximately 3% of all DILI cases. The hepatotoxicity of many drugs, including the antimycotics, is poorly screened in human models. Methods. In a standardized assay the cytotoxicity on hepatocytes of different concentrations ( C max, 5x C max, and 10x C max) of the antimycotics used for systemic infections was tested. Anidulafungin (ANI), liposomal amphotericerin B (L-AmB), caspofungin (CASPO), fluconazole (FLUCO), and voriconazole (VORI) were incubated with HepG2/C3A cells. After incubation, the viability of cells (XTT test, LDH release, trypan blue staining), the synthesis of albumin, the cytochrome 1A2 activity, and the cell death (DNA fragmentation) were determined. Kruskal-Wallis and Mann-Whitney tests were used for statistical analyses. Results. L-AmB, ANI, and CASPO showed a mild hepatotoxicity in the C max concentrations. Higher concentrations of anidulafungin led to a severe impairment of hepatocyte viability and function. The azoles FLUCO and VORI had a higher hepatotoxic potential in all concentrations. Conclusion. Antimycotics, especially azoles, used for systemic infections should be given with caution in patient with liver insufficiency or liver failure or high risk for this; therefore, therapeutic drug monitoring should be used. Further studies with this approach are encouraged.
- Published
- 2017
- Full Text
- View/download PDF
39. Molecular adsorbent recirculating system and single-pass albumin dialysis in liver failure--a prospective, randomised crossover study.
- Author
-
Sponholz C, Matthes K, Rupp D, Backaus W, Klammt S, Karailieva D, Bauschke A, Settmacher U, Kohl M, Clemens MG, Mitzner S, Bauer M, and Kortgen A
- Subjects
- Bile Acids and Salts blood, Bilirubin blood, Biomarkers blood, Creatinine blood, Cross-Over Studies, Extracorporeal Circulation methods, Female, Fluid Therapy adverse effects, Fluid Therapy methods, Humans, Male, Middle Aged, Prospective Studies, Urea blood, Liver Failure blood, Renal Dialysis adverse effects, Renal Dialysis standards, Serum Albumin metabolism
- Abstract
Background: The aim of extracorporeal albumin dialysis (ECAD) is to reduce endogenous toxins accumulating in liver failure. To date, ECAD is conducted mainly with the Molecular Adsorbents Recirculating System (MARS). However, single-pass albumin dialysis (SPAD) has been proposed as an alternative. The aim of this study was to compare the two devices with a prospective, single-centre, non-inferiority crossover study design with particular focus on reduction of bilirubin levels (primary endpoint) and influence on paraclinical and clinical parameters (secondary endpoints) associated with liver failure., Methods: Patients presenting with liver failure were screened for eligibility and after inclusion were randomly assigned to be started on either conventional MARS or SPAD (with 4% albumin and a dialysis flow rate of 700 ml/h). Statistical analyses were based on a linear mixed-effects model., Results: Sixty-nine crossover cycles of ECAD in 32 patients were completed. Both systems significantly reduced plasma bilirubin levels to a similar extent (MARS: median -68 μmol/L, interquartile range [IQR] -107.5 to -33.5, p = 0.001; SPAD: -59 μmol/L, -84.5 to +36.5, p = 0.001). However, bile acids (MARS: -39 μmol/L, -105.6 to -8.3, p < 0.001; SPAD: -9 μmol/L, -36.9 to +11.4, p = 0.131), creatinine (MARS: -24 μmol/L, -46.5 to -8.0, p < 0.001; SPAD: -2 μmol/L, -9.0 to +7.0/L, p = 0.314) and urea (MARS: -0.9 mmol/L, -1.93 to -0.10, p = 0.024; SPAD: -0.1 mmol/L, -1.0 to +0.68, p = 0.523) were reduced and albumin-binding capacity was increased (MARS: +10%, -0.8 to +20.9%, p < 0.001; SPAD: +7%, -7.5 to +15.5%, p = 0.137) only by MARS. Cytokine levels of interleukin (IL)-6 and IL-8 and hepatic encephalopathy were altered by neither MARS nor SPAD., Conclusions: Both procedures were safe for temporary extracorporeal liver support. While in clinical practice routinely assessed plasma bilirubin levels were reduced by both systems, only MARS affected other paraclinical parameters (i.e., serum bile acids, albumin-binding capacity, and creatinine and urea levels). Caution should be taken with regard to metabolic derangements and electrolyte disturbances, particularly in SPAD using regional citrate anti-coagulation., Trial Registration: German Clinical Trials Register ( www.drks.de) DRKS00000371. Registered 8 April 2010.
- Published
- 2016
- Full Text
- View/download PDF
40. Response to Therapeutic Plasma Exchange as a Rescue Treatment in Clinically Isolated Syndromes and Acute Worsening of Multiple Sclerosis: A Retrospective Analysis of 90 Patients.
- Author
-
Ehler J, Koball S, Sauer M, Mitzner S, Hickstein H, Benecke R, and Zettl UK
- Subjects
- Adolescent, Adult, Aged, Demyelinating Diseases pathology, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Multiple Sclerosis pathology, Plasma Exchange adverse effects, Recurrence, Retrospective Studies, Treatment Outcome, Young Adult, Demyelinating Diseases therapy, Multiple Sclerosis therapy, Plasma Exchange methods
- Abstract
Objectives: Experience with therapeutic plasma exchange (TPE) for acute relapses in clinically isolated syndrome (CIS) or multiple sclerosis (MS) patients has been derived from small and inhomogeneous patient populations so far. In the present study, we retrospectively evaluated features associated with TPE response in a larger cohort of CIS and MS patients with acute worsening of disease., Participants: Ninety CIS and MS patients with acute relapses or acute worsening of symptoms were firstly treated with TPE. The population consisted of 62 women and 28 men with a median age of 38 years (range 18-69 years)., Outcome Measures: Primary endpoint was the clinical response to TPE, focused on the functional improvement of the target neurologic deficit. Secondary endpoint was an improvement in expanded disability status scale (EDSS) scoring., Results: A clinical response to TPE was observed in 65 out of 90 patients (72.2%), with marked improvement in 18 (20.0%) and moderate improvement in 47 out of 90 patients (52.2%). The median EDSS was reduced from 3.75 before to 3.0 after TPE (p = 0.001). Response to TPE was significantly more frequent in patients with relapsing courses of disease (CIS, RR-MS, p = 0.001), no disease modifying drugs (p = 0.017), gadolinium-positive (Gd+) MRI lesions (p = 0.001) and EDSS ≤ 5.0 before TPE (p = 0.014). In the multiple logistic regression analysis only the detection of Gd+ MRI lesions was significantly altered (p = 0.004)., Conclusion: Clinical response to TPE was achieved in the majority of our patients. We identified clinical and diagnostic features in CIS and MS relapses that might be helpful to identify patients responding to TPE. Gd+ MRI lesions before treatment were the best predictor of the response to TPE in our cohort.
- Published
- 2015
- Full Text
- View/download PDF
41. Establishment of a novel extracorporeal bowel model to study luminal approaches to treat inflammatory bowel disease.
- Author
-
Breitrück A, Sparmann G, Mitzner S, and Kerkhoff C
- Subjects
- Animals, Cytokines metabolism, Inflammatory Bowel Diseases metabolism, Male, Rats, Rats, Inbred Lew, Reverse Transcriptase Polymerase Chain Reaction, Inflammatory Bowel Diseases therapy, Models, Biological
- Abstract
We have established an extracorporeal bowel model system for the analysis of early events in inflammatory bowel disease (IBD) and therapeutic applications. This model consists of an intestinal segment that is cannulated and perfused in situ, allowing the investigation of cellular responses of apical mucosa cells on luminal applied substances. Short-term treatment with iodoacetamide mimicked experimental intestinal inflammation in IBD, as indicated by histological alterations such as hemorrhage, hyperemia and loss of regular crypt architecture, as well as enhanced expression of cytokines (e.g. IL-6, IL-10 and MCP-1) compared with control segments perfused with media. Perfusion of therapeutic agents (e.g. dexamethasone or Mutaflor) in the small intestine segment significantly reduced the features of early inflammation that are induced by iodoacetamide. Moreover, similar data were obtained for Resormin(®), a montmorillonite-illite mixed-layer mineral (smectite), indicating that smectites might be a newly identified therapeutic option for IBD. In summary, this model could provide novel insights into epithelial injury as well as genesis of IBD and, therefore, be useful in testing the therapeutic potential of compounds for IBD therapy.
- Published
- 2013
- Full Text
- View/download PDF
42. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry.
- Author
-
Kielstein JT, Beutel G, Fleig S, Steinhoff J, Meyer TN, Hafer C, Kuhlmann U, Bramstedt J, Panzer U, Vischedyk M, Busch V, Ries W, Mitzner S, Mees S, Stracke S, Nürnberger J, Gerke P, Wiesner M, Sucke B, Abu-Tair M, Kribben A, Klause N, Schindler R, Merkel F, Schnatter S, Dorresteijn EM, Samuelsson O, and Brunkhorst R
- Subjects
- Adult, Aged, Aged, 80 and over, Epidemics, Escherichia coli Infections epidemiology, Escherichia coli Infections microbiology, Female, Germany epidemiology, Hemolytic-Uremic Syndrome mortality, Humans, Male, Middle Aged, Registries, Retrospective Studies, Treatment Outcome, Young Adult, Antibodies, Monoclonal, Humanized therapeutic use, Escherichia coli Infections complications, Hemolytic-Uremic Syndrome etiology, Hemolytic-Uremic Syndrome therapy, Plasma Exchange, Shiga-Toxigenic Escherichia coli pathogenicity
- Abstract
Background: May 22nd marks the beginning of a Shiga-toxin-producing Escherichia coli (STEC) O104:H4 outbreak in Northern Germany. By its end on 27 July, it had claimed 53 deaths among 2987 STEC and 855 confirmed haemolytic-uraemic syndrome (HUS) cases., Methods: To describe short-term effectiveness of best supportive care (BSC), therapeutic plasma exchange (TPE) and TPE with eculizumab (TPE-Ecu) in 631 patients with suspected HUS treated in 84 hospitals in Germany, Sweden and the Netherlands using the web-based registry of the DGfN (online since 27 May)., Results: Of 631 entries, 491 fulfilled the definition of HUS (median age 46 years; 71% females). The median (inter-quartile range) hospital stay was 22 (14-31) days. Two hundred and eighty-one (57%) patients underwent dialysis and 114 (23%) mechanical ventilation. Fifty-seven patients received BSC, 241 TPE and 193 TPE-Ecu. Treatment strategy was dependent on disease severity (laboratory signs of haemolysis, thrombocytopenia, peak creatinine level, need for dialysis, neurological symptoms, frequency of seizures) which was lower in BSC than in TPE and TPE-Ecu patients. At study endpoint (hospital discharge or death), the median creatinine was lower in BSC [1.1 mg/dL (0.9-1.3)] than in TPE [1.2 mg/dL (1.0-1.5), P < 0.05] and TPE-Ecu [1.4 mg/dL (1.0-2.2), P < 0.001], while need for dialysis was not different between BSC (0.0%, n = 0), TPE (3.7%; n = 9) and TPE-Ecu (4.7%, n = 9). Seizures were absent in BSC and rare in TPE (0.4%; n = 1) and TPE-Ecu (2.6%; n = 5) patients. Total hospital mortality in HUS patients was 4.1% (n = 20) and did not differ significantly between the TPE and TPE-Ecu groups., Conclusions: Despite frequent renal impairment, advanced neurological disorders and severe respiratory failure, short-term outcome was better than expected when compared with previous reports. Within the limitations of a retrospective registry analysis, our data do not support the notion of a short-term benefit of Ecu in comparison to TPE alone in the treatment of STEC-HUS. A randomized trial comparing BSC, TPE and Ecu seems to be prudent and necessary prior to establishing new treatment guidelines for STEC-HUS.
- Published
- 2012
- Full Text
- View/download PDF
43. Albumin-binding capacity (ABiC) is reduced in patients with chronic kidney disease along with an accumulation of protein-bound uraemic toxins.
- Author
-
Klammt S, Wojak HJ, Mitzner A, Koball S, Rychly J, Reisinger EC, and Mitzner S
- Subjects
- Aged, Cross-Sectional Studies, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prognosis, Fluorescent Dyes metabolism, Kidney Failure, Chronic metabolism, Kidney Failure, Chronic pathology, Serum Albumin metabolism, Toxins, Biological metabolism, Uremia metabolism
- Abstract
Background: Albumin is an important transport protein for non-water-soluble protein-bound drugs and uraemic toxins. Its transport capacity is reduced in patients with advanced chronic kidney disease (CKD) and unbound fractions of uraemic toxins are related to complications of CKD. We investigated whether this reduction could be quantified and how it correlated with the stages of CKD. Albumin-binding capacity (ABiC) is a dye-based method that quantifies the remaining binding capacity of one major binding site (site II) of the albumin molecule., Methods: Blood samples from 104 CKD patients were incubated with a binding site-specific fluorescent marker and the amount of unbound marker was determined by means of fluorescence detection after filtration. Measurements in a pooled human plasma were used for reference. Glomerular filtration rate and serum indoxyl sulphate (IS) levels were also determined., Results: Impairment of renal function was associated with a reduction in ABiC (mean ± SD: 118 ± 12; 111 ± 11; 99 ± 8 and 79 ± 9% for Stages 1/2, 3, 4 and 5, respectively; P < 0.001) and an increase in IS (3.9 ± 1.1; 6.2 ± 3.2; 16.3 ± 14.9 and 56.1 ± 28.6 μmol/L for Stages 1/2, 3, 4 and 5, respectively; P < 0.001). In dialysis patients, ABiC was lower in those with urine outputs <500 mL/day than in those with preserved urine output (73.7 ± 6.0 versus 83.8 ± 8.5%; P < 0.001)., Conclusion: Impaired albumin function in CKD patients can be quantified, is related to severity of kidney disease and is associated with an accumulation of uraemic albumin-bound retention solutes.
- Published
- 2012
- Full Text
- View/download PDF
44. Industrial stabilizers caprylate and N-acetyltryptophanate reduce the efficacy of albumin in liver patients.
- Author
-
Stange J, Stiffel M, Goetze A, Strube S, Gruenert J, Klammt S, Mitzner S, Koball S, Liebe S, and Reisinger E
- Subjects
- Aged, Albumins administration & dosage, Albumins pharmacology, Blood Volume drug effects, Caprylates pharmacology, Charcoal, Feasibility Studies, Female, Humans, Hypertension, Portal physiopathology, Infusions, Intravenous, Kidney drug effects, Kidney physiology, Liver Cirrhosis physiopathology, Male, Middle Aged, Pilot Projects, Treatment Outcome, Tryptophan adverse effects, Tryptophan pharmacology, Albumins therapeutic use, Caprylates adverse effects, Hypertension, Portal drug therapy, Liver Cirrhosis drug therapy, Tryptophan analogs & derivatives
- Abstract
Liver failure is associated with an accumulation of toxic molecules that exert an affinity to albumin. Some of them have vasoactive activity. So far, albumin has been used as a plasma expander to improve the available circulating blood volume. However, recent studies have suggested that albumin is more effective than starch for this indication. It has not been reported yet whether the industrial stabilizers octanoate and N-acetyltryptophanate, added to albumin, occupy binding sites for vasoactive substances. The aim of this study was to determine whether the presence of the industrial stabilizers octanoate and caprylate has an impact on the effect of the albumin-binding function or circulating blood volume in patients with cirrhosis, portal hypertension, and an indication for albumin. In 25 patients who received albumin via an inline infusion filter that depleted stabilizers, there was an improvement of albumin binding, and there was less deterioration of circulating blood volume and renal function in comparison with a control group. Further studies are needed to confirm the results and identify the potential socioeconomic side effects of industrial stabilizers in commercial albumin solutions., (Copyright © 2011 American Association for the Study of Liver Diseases.)
- Published
- 2011
- Full Text
- View/download PDF
45. Liver support by extracorporeal blood purification: a clinical observation.
- Author
-
Stange J, Mitzner SR, Klammt S, Freytag J, Peszynski P, Loock J, Hickstein H, Korten G, Schmidt R, Hentschel J, Schulz M, Löhr M, Liebe S, Schareck W, and Hopt UT
- Subjects
- Adult, Female, Humans, Liver Failure blood, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Extracorporeal Circulation, Inactivation, Metabolic, Liver metabolism, Liver Failure metabolism, Renal Dialysis, Toxins, Biological blood
- Abstract
Liver failure associated with excretory insufficiency and jaundice results in an endogenous accumulation of toxins involved in the impairment of cardiovascular, kidney, and cerebral function. Moreover, these toxins have been shown to damage the liver itself by inducing hepatocellular apoptosis and necrosis, thus creating a vicious cycle of the disease. We report a retrospective cohort study of 26 patients with acute or chronic liver failure with intrahepatic cholestasis (bilirubin level > 20 mg/dL) who underwent a new extracorporeal blood purification treatment. A synthetic hydrophilic/hydrophobic domain-presenting semipermeable membrane (pore size < albumin size, 100-nm thick) was used for extracorporeal blood detoxification using dialysis equipment. The opposite side was rinsed with ligandin-like proteins as molecular adsorbents that were regenerated online using a chromatography-like recycling system (molecular adsorbent recirculating system [MARS]). Bile acid and bilirubin levels, representing the previously described toxins, were reduced by 16% to 53% and 10% to 90% of the initial concentration by a single treatment of 6 to 8 hours, respectively. Toxicity testing of patient plasma onto primary rat hepatocytes by live/dead fluorescence microscopy showed cell-damaging effects of jaundiced plasma that were not observed after treatment. Patients with a worsening of Child-Turcotte-Pugh (CTP) index before the treatments showed a significant improvement of this index during a period of 2 to 14 single treatments with an average of 14 days. After withdrawal of MARS treatment, this improvement was sustained in all long-term survivors. Ten patients represented a clinical status equivalent to the United Network for Organ Sharing (UNOS) status 2b (group A1), and all survived. Sixteen patients represented a clinical status equivalent to UNOS status 2a, and 7 of these patients survived (group A2), whereas 9 patients (group B) died. We conclude that in acute excretory failure caused by a chronic liver disease, this treatment provides a therapy option to remove toxins involved in multiorgan dysfunction secondary to liver failure.
- Published
- 2000
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.